<div id="readability-page-1">By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported 2025 financial and operational results in a March 23rd, 2026, press release. For the year, it produced license revenues of $1.2 million and a net operating loss of $10.3 million. The joint venture (JV) with Hemispherian, called Tetragon Biosciences, expects to begin screening patients by the end of this month for the glioblastoma...</div>

BLRX

<p>BioLineRx Ltd. (NASDAQ: BLRX) reported its 2025 financial results, revealing license revenues of $1.2 million and a net operating loss of $10.3 million. The company announced that its joint venture with Hemispherian, Tetragon Biosciences, is set to begin patient screening for glioblastoma by the end of March 2026.</p>

BLRX: Full year 2025 results